81009
document
Using repeated measures of symptom score , uroflowmetry and prostate specific antigen in the clinical management of prostate disease . Benign Prostatic Hyperplasia Treatment Outcomes Study Group . Measurements of American Urological Association symptom score , peak urine flow rate and prostate specific antigen ( PSA ) are often followed over time in urological management . However , their interpretation is confounded by within-patient variability due to chance . Data from 2 clinical trials are used to examine the magnitude of this variation . When these measures are repeated at a short interval variation is modest and might easily be misinterpreted as a true change in patient condition . For example , approximately 20 % of patients might be expected to have a chance increase or decrease in symptom score by at least 4.9 points , in peak urine flow rate by at least 4.1 ml . per second or in PSA by at least 1.6 ng./ml . Clinicians can use these data to help interpret repeated measures of these variables in patients , and can consider obtaining paired measurements to decrease the effect of chance variation when they plan on following them over time .
81010
Intervention_Physical
Measurements of American Urological Association symptom score , peak urine flow rate and prostate specific antigen ( PSA )
81011
Intervention_Educational
urological management .
81012
Outcome_Physical
American Urological Association symptom score
81013
Outcome_Physical
peak urine flow rate
81014
Outcome_Physical
prostate specific antigen ( PSA )
81015
Participant_Condition
prostate disease
81016
Participant_Condition
Benign Prostatic Hyperplasia